BriaCell Therapeutics Corp. a clinical-stage biotechnology company specializing ... sessions during the 2022 San Antonio Breast Cancer Symposium ® .
News
- BriaCell Announces Positive Clinical and Quality of Life Data in ... - Investing News Network
- Oncolytics' Chinese Partner Adlai Nortye Reports Interim Results Of Pelareorep-paclitaxel
(RTTNews) - Oncolytics Biotech Inc. (ONCY)'s Chinese partner Adlai Nortye ... The company presented the data at the San Antonio Breast Cancer ...
- Oncolytics Biotech's® Chinese Development Partner Adlai Nortye Presents Interim Clinical ...
Oncolytics Biotech's® Chinese Development Partner Adlai Nortye Presents ... Metastatic Breast Cancer at the San Antonio Breast Cancer Symposium.
- SABCS Data Solidifies Enhertu as Preferred Second-, Third-Line HER2-Positive Breast ...
SAN ANTONIO – Two Phase II trials of Daiichi Sankyo and AstraZeneca's Enhertu (trastuzumab deruxtecan) confirmed the drug's benefit as a second- ...
- DFS Improved With AIs vs Tamoxifen in HR+, HER2- Early Breast Cancer
... presented in a poster at the San Antonio Breast Cancer Symposium 2022. ... Disclosures: Some study authors declared affiliations with biotech, ...